Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer

Cisplatin (CDDP)-based combination chemotherapy remains the mainstream treatment for advanced bladder cancer. However, its efficacy is often limited due to the development of resistance for which underlying mechanisms are poorly understood. Meanwhile, emerging evidence has indicated the involvement...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Eiji, Ide, Hiroki, Inoue, Satoshi, Kawahara, Takashi, Zheng, Yichun, Reis, Leonardo O., Baras, Alexander S., Miyamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226499/
https://www.ncbi.nlm.nih.gov/pubmed/27322140
http://dx.doi.org/10.18632/oncotarget.9994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226499/
https://www.ncbi.nlm.nih.gov/pubmed/27322140
http://dx.doi.org/10.18632/oncotarget.9994

Ejemplares similares